Objective To analyze the application value of tumor markers combined with low-dose CT(LDCT)technology in the early diagnosis of non-small cell lung cancer(NSCLC).Methods 47 patients with early NSCLC treated in Affiliated Hospital of Jining Medical University from January 2022 to December 2023 were selected as the observation group,and 47 patients with benign lung lesions during the same period were selected as the control group.LDCT technology was performed on all study subjects,and tumor marker levels were detected.The role of LDCT technology combined with tumor markers in the early diagnosis of NSCLC was analyzed.Results Serum carcinoembryonic antigen(CEA),cytokeratin fragment 21-1(CYFRA21-1),neuron specific enolase(NSE)levels in early NSCLC patients and patients with benign lung lesions There was a significant difference in blood volume(BV)and Perfusion levels(P＜0.05).LDCT and serum CEA The AUC,sensitivity,and specificity of CYFRA21-1 and NSE combined detection were 0.952、91.49％,and 87.23％,respectively.Conclusion In the early diagnosis of NSCLC,the combined diagnosis of LDCT and tumor markers has high application value.
维普
万方数据
